β-catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E-cadherin/CDH1, N-cadherin/CDH2, VE-cadherin/CDH5 and α-catenins), transmembrane-type mucins (MUC1/CD227 and MUC16/CA125), signaling regulators (APC, AXIN1, AXIN2 and NHERF1/EBP50) and epigenetic or transcriptional regulators (BCL9, BCL9L, CREBBP/CBP, EP300/p300, FOXM1, MED12, SMARCA4/BRG1 and TCF/LEF). Gain-of-function CTTNB1 mutations are detected in bladder cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer and uterine cancer, whereas loss-of-function CTNNB1 mutations are also detected in human cancer. ABCB1, ALDH1A1, ASCL2, ATF3, AXIN2, BAMBI, CCND1, CD44, CLDN1, CTLA4, DKK1, EDN1, EOMES, FGF18, FGF20, FZD7, IL10, JAG1, LEF1, LGR5, MITF, MSX1, MYC, NEUROD1, NKD1, NODAL, NOTCH2, NOTUM, NRCAM, OPN, PAX3, PPARD, PTGS2, RNF43, SNAI1, SP5, TCF7, TERT, TNFRSF19, VEGFA and ZNRF3 are representative β-catenin target genes. β-catenin signaling is involved in myofibroblast activation and subsequent pulmonary fibrosis, in addition to other types of fibrosis. β-catenin and NF-κB signaling activation are involved in field cancerization in the stomach associated with Helicobacter pylori (H. pylori) infection and in the liver associated with hepatitis C virus (HCV) infection and other etiologies. β-catenin-targeted therapeutics are functionally classified into β-catenin inhibitors targeting upstream regulators (AZ1366, ETC-159, G007-LK, GNF6231, ipafricept, NVP-TNKS656, rosmantuzumab, vantictumab, WNT-C59, WNT974 and XAV939), β-catenin inhibitors targeting protein-protein interactions (CGP049090, CWP232228, E7386, ICG-001, LF3 and PRI-724), β-catenin inhibitors targeting epigenetic regulators (PKF118-310), β-catenin inhibitors targeting mediator complexes (CCT251545 and cortistatin A) and β-catenin inhibitors targeting transmembrane-type transcriptional outputs, including CD44v6, FZD7 and LGR5. Eradicating H. pylori and HCV is the optimal approach for the first-line prevention of gastric cancer and hepatocellular carcinoma (HCC), respectively. However, β-catenin inhibitors may be applicable for the prevention of organ fibrosis, second-line HCC prevention and treating β-catenin-driven cancer. The multi-layered prevention and treatment strategy of β-catenin-related human diseases is necessary for the practice of personalized medicine and implementation of precision medicine.
The CTNNB1 gene encodes the intracellular scaffold protein β-catenin (1), which interacts with adhesion molecules (E-cadherin/CDH1, N-cadherin/CDH2, VE-cadherin/CDH5 and α-catenins) (2,3), transmembrane mucins (MUC1/CD227 and MUC16/CA125) (4,5), cytoplasmic signaling regulators (APC, AXIN1, AXIN2, BTRC/βTRCP1, BTRC2/βTRCP2 and NHERF1/EBP50) (6,7), and nuclear transcriptional regulators (BCL9, BCL9L, CREBBP/CBP, EP300/p300, FOXM1, LEF1/TCF7L3, MED12, SMARCA4/BRG1, SPDEF, TCF7/TCF-1, TCF7L1/TCF-3 and TCF7L2/TCF-4) (8-10). Based on protein-protein interactions (PPIs), β-catenin is involved in cell-cell adhesion, cellular signaling and transcriptional regulation (Fig. 1A).
β-catenin undergoes post-translational modifications, including acetylation, glycosylation, methylation, phosphorylation and ubiquitylation. Oncogenic tyrosine kinases phosphorylate β-catenin at Y654 to release β-catenin from cadherin complexes, whereas canonical WNT signals prevent the phosphorylation of β-catenin at S33, S37, T41 and S45 to release β-catenin from ubiquitylation-mediated degradation (1). The β-TRCP complex is involved in the poly-ubiquitylation of S33/S37/T41/S45-phosphorylated β-catenin and subsequent proteasome-mediated degradation (9,11), whereas USP7 is involved in the de-ubiquitylation and stabilization of β-catenin (12). Stabilized β-catenin is translocated into the nucleus to activate the transcription of TCF/LEF target genes (Fig. 1B). The acetylation of β-catenin at K49 leads to transcriptional activation, whereas the methylation of β-catenin at K49 leads to transcriptional repression (13,14). The functions of β-catenin are regulated by its localization, PPIs and stability based on post-translational modifications.
Representative β-catenin target genes (Fig. 1C) include ABCB1, ALDH1A1, ASCL2, ATF3, AXIN2, BAMBI, CCND1 (Cyclin D1), CD44, Claudin-1 (CLDN1), CTLA4, DKK1, EDN1, EOMES, FGF18, FGF20, FZD7, GBX1, IL10 (IL-10), Jagged-1 (JAG1), LEF1, LGR5, MITF, MSX1, MYC (c-Myc), NEUROD1, NKD1, NODAL, NOTCH2, NOTUM, NRCAM, osteopontin (OPN), PAX3, PPARD, PTGS2 (COX2), RNF43, SNAI1 (Snail), SP5, TCF7, TERT, TNFRSF19 (Troy), VEGFA (VEGF) and ZNRF3 (1,15-28). CTTTGATAT is the consensus DNA-binding motif of TCF-3, whereas CTCGCGAGA is the major DNA-binding motif of TCF-1 (29). By contrast, lysine acetyltransferases CBP and p300 are reported to differentially regulate β-catenin-dependent transcriptional programs in stem cells to propel them towards self-renewal and differentiation, respectively (30). β-catenin target genes are upregulated in a cell context-dependent manner based on the epigenetic status of their regulatory regions and availability of transcriptional regulators (1).
Inflammation is an immune response to repair tissue damage caused by infectious agents, environmental stimuli and endogenous irritants. The failure to resolve acute inflammation leads to chronic inflammation characterized by the continuous activation of macrophages and lymphocytes in the inflamed tissue microenvironment and elevated levels of the pro-inflammatory cytokines IL-1β, IL-6, IL-17 and TNF-α (31,32). Chronic persistent inflammation then leads to the collapse of homeostatic interactions among epithelial cells, stromal cells and immune cells in the tissue microenvironment, which causes organ fibrosis through the myofibroblast-like transition of tissue-resident fibroblasts, stellate cells or bone marrow-derived fibrocytes, and the subsequent deposition of extracellular matrix (ECM) components, including collagen, fibronectin and hyaluronan (Fig. 2A).
β-catenin signaling dysregulation is involved in chronic inflammation, organ fibrosis, and various types of human cancer (1,33). However, β-catenin-targeted therapy is not yet approved for the treatment of patients with β-catenin-related diseases. As β-catenin is an intracellular protein without intrinsic enzymatic activity, it is difficult to target β-catenin for drug development. In this review, gain- and loss-of-function β-catenin alterations in human cancer types are summarized, and the pathophysiology of β-catenin-related chronic inflammation and/or organ fibrosis are presented with emphases on carcinogenesis in the stomach, liver and lungs. Finally, the development of β-catenin inhibitors targeting its upstream regulators, PPIs and downstream effectors are reviewed.
2. Gain- and loss-of-function β-catenin alterations in human cancer
β-catenin-dependent transcription is aberrantly activated in human cancer due to gain-of-function mutations in the CTNNB1 gene itself, in addition to genetic alterations in the APC, AXIN2, RNF43 and RSPO3 genes involved in the canonical WNT/β-catenin signaling cascade, upregulation of canonical WNT ligands in the tumor microenvironment, or Y654 phosphorylation of β-catenin by oncogenic tyrosine kinases, including BCR-ABL1 fusion, FLT3-ITD mutation and overexpression of MET (34).
Missense mutations at or in-frame deletions around S33, S37, T41 and S45 in β-catenin give rise to gain-of-function β-catenin mutants that are resistant to ubiquitylation-mediated proteasomal degradation and induce the upregulation of oncogenic target genes, including CCND1 and MYC, in adrenocortical tumors, bladder cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer and uterine cancer (35-40). Aberrant β-catenin-dependent transcriptional activation drives human carcinogenesis through the induction of cancer stem cell (CSC) features, bulk tumor proliferation and the epithelial-to-mesenchymal transition (EMT) in the solid tumors mentioned above.
By contrast, nonsense or frame-shift mutations in β-catenin, including R95*, K335fs, R449fs, E458fs, R474*, R535*, E571* and E642fs, also occur in human cancer, including gastric cancer and head and neck squamous cell carcinoma (37,41-43). In melanoma, decreased β-catenin not only promotes invasion and metastasis through disrupted cell-cell adhesion but also resistance to targeted therapy through MITF/APE1 axis repression (44,45). Ctnnb1 haploinsufficiency has been shown to promote aggressiveness and metastasis in a mouse model of HER2-positive basal breast cancer (46). β-catenin exerts not only oncogenic but also tumor-suppressor functions in a context-dependent manner.
β-catenin mutations are classified as i) gain-of-function mutations clustered at or around S33, S37, T41 and S45, ii) loss-of-function mutations due to nonsense or frame-shift mutations and iii) other mutations to be further characterized. In addition to these coding mutations, copy number gain (47) and regulatory mutations in the proximal promoter region (48) of the CTNNB1 gene encoding β-catenin have been reported in prostate cancer and breast cancer, respectively. Owing to the pro- and anti-oncogenic roles of β-catenin, integrative omics analyses, including whole-genome sequencing, transcriptome and immunohistochemical analyses, are necessary to precisely prescribe β-catenin-targeted therapeutics in personalized or precision medicine in the future.
3. Activation of β-catenin in chronic gastritis and gastric cancer associated with Helicobacter pylori infection
Helicobacter pylori (H. pylori) is a Gram-negative, helical rod-shaped microaerophilic bacterium that specifically colonizes the human stomach through interactions between bacterial BabA and HopQ adhesins to host ABO blood antigens and CEACAM, respectively (49,50). H. pylori secretes urease for ammonia production from urea to survive in an microenvironment of high acidity, and they deliver CagA, VacA, γ-glutamyl transpeptidase and other virulence factors to the gastric microenvironment to elicit epithelial polarity dysregulation and mucosal damage, leading to pro-inflammatory cytokine secretion and immune tolerance (51,52). Cytokine-mediated T helper cell (Th)1 and Th17 responses induce anti-H. pylori acquired immunity within H. pylori-colonized microenvironments, whereas the dendritic cell (DC)-mediated expansion of regulatory T (Treg) cells leads to immune evasion within the gastric microenvironment and cross-tolerance to allergens in extra-gastric microenvironments (51,53).
In human organoid culture systems infected with H. pylori, CagA is injected into epithelial cells through the type IV secretion system and associates with the HGF receptor (MET) and hyaluronan receptor (CD44) to promote epithelial proliferation, in part through β-catenin signaling activation (54-56). By contrast, in a mouse model with artificial H. pylori infection, Rspo3 is upregulated to expand Lgr5+ gastric stem/progenitor cells (57). As WNT2B (WNT-13) was originally cloned and characterized as a canonical WNT ligand derived from the human stomach (58,59), RSPO3 can enhance canonical WNT/β-catenin signaling activation through the release of Frizzled family WNT receptors from RNF43/ZNRN3-mediated repression (1,60) and thus promote epithelial proliferation and gastric hyperplasia. The WNT/β-catenin signaling cascade is aberrantly activated in human gastric cancer due to gain-of-function mutations in the CTNNB1 gene, as mentioned above, and to loss-of-function mutations in the APC and RNF43 genes (37). Together, these findings indicate that β-catenin serves key roles in H. pylori-related chronic active gastritis and gastric cancer.
Decades of persistent H. pylori infection lead to field cancerization in the stomach (Fig. 2B) through the sequential progression of chronic active gastritis, fundic gland atrophy, intestinal metaplasia and gastric cancer (61-63). Although H. pylori eradication in relatively older patients with irreversible gastric atrophy and intestinal metaplasia may not contribute to the prevention of gastric carcinogenesis due to preexisting genetic and epigenetic alterations in the premalignant lesions, H. pylori eradication in relatively younger patients with chronic active gastritis and/or reversible atrophy is optimal for the prevention of gastric carcinogenesis (Fig. 2C). A triple or quadruple regimen (proton-pump inhibitor, amoxicillin and clarithromycin with or without metronidazole) is prescribed for the eradication of H. pylori (64-67). To avoid the prevalence of drug-resistant H. pylori, the quadruple regimen is recommended for H. pylori eradication in Canada, Europe and the US.
By contrast, atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab are representative immune checkpoint inhibitors that are approved for the treatment of patients with certain types of cancer (34,68). As H. pylori eradication eliminates H. pylori-related chronic inflammation and H. pylori-specific immune evasion, and reduces non-specific immune evasion caused by the DC-mediated Treg expansion and IL-10 elevation in the gastric microenvironment, H. pylori eradication may synergize with immune checkpoint inhibitors for the treatment of advanced gastric cancer with chronic active gastritis.
4. Activation of β-catenin in liver fibrosis and hepatocellular carcinoma
Chronic liver inflammation associated with hepatitis C virus (HCV) infection, hepatitis B virus (HBV) infection, alcohol abuse, non-alcoholic fatty liver disease and other etiologies leads to liver fibrosis due to the myofibroblast-like transition of hepatic stellate cells or other mesenchymal cells and subsequent accumulation of excessive ECM (31,33). Liver cirrhosis is the most advanced stage of liver fibrosis, which is characterized by impaired liver functions and complications, including ascites, hepatic encephalopathy and upper gastrointestinal bleeding. Persistent liver inflammation leads to field cancerization in the liver through the sequential progression of chronic hepatitis, liver fibrosis and hepatocellular carcinoma (HCC) (69), similar to H. pylori-related field cancerization in the stomach (Fig. 2C).
The canonical WNT/β-catenin signaling cascade is involved in the development and homeostasis of the liver (70,71). Canonical WNT/β-catenin signals promote the proliferation of LGR5+ hepatocyte progenitors in the peri-venous zone of hepatic lobules, whereas non-canonical WNT and other signals promote the proliferation of cholangiocyte progenitors in the peri-portal zone of hepatic lobules (71-73). Canonical Wnt-dependent Lgr5+ liver stem/progenitor cells in an organoid culture have successfully been applied in transplantation therapy for liver failure in a rat model (74).
HCV is a single-stranded RNA virus that infects hepatocytes to produce Core, NS3/4A, NS5A, NS5B and other viral proteins, and HCV upregulates the expression of β-catenin and MYC in hepatocytes (69). HBV is a partially double-stranded DNA virus that infects hepatocytes to produce HBx, pre-S, S and other viral proteins, and HBx upregulates the expression of EPCAM, β-catenin and MYC and activates NF-κB signaling in hepatocytes (69). The RSPO-dependent activation of the WNT/β-catenin signaling cascade is involved in the activation of hepatic stellate cells to promote liver fibrosis (75), whereas a β-catenin inhibitor (PRI-724) has been shown to prevent HCV-related liver fibrosis in a mouse model (76). By contrast, the WNT/β-catenin signaling cascade is aberrantly activated in human HCC due to gain-of-function mutations in the CTNNB1 gene and loss-of-function mutations in the APC and AXIN1 genes (35). Additionally, gain-of-function β-catenin mutations (S33Y or S45Y) and the overexpression of Met have been shown to synergistically promote liver tumorigenesis in a mouse model (77), whereas an oncolytic adenovirus Ad.wnt-E1A(Δ24 bp)-TSLC1 has been shown to effectively target liver cancer cells with aberrant β-catenin-TCF/LEF signaling activation and repress in vivo tumorigenesis and metastasis (78). β-catenin plays key roles in multiple processes of chronic inflammation-related liver pathophysiology, including hepatocyte proliferation, stellate-cell activation, liver fibrosis and liver tumorigenesis.
The eradication of HCV is predicted to be an optimal approach to prevent HCC; as such, the eradication of H. pylori may be used to prevent gastric cancer. Direct-acting antivirals, including HCV NS3/4A protease inhibitors (glecaprevir and paritaprevir), HCV NS5A inhibitors (ledipasvir, ombitasvir, pibrentasvir and velpatasvir) and HCV NS5B RNA polymerase inhibitors (dasabuvir and sofosbuvir), have been developed for the eradication of HCV. For example, glecaprevir/pibrentasvir and velpatasvir/sofosbuvir are combination drugs that are approved for the treatment of HCV genotypes 1, 2, 3, 4, 5 and 6 (79,80). Studies in Italy and Spain revealed that the occurrence and recurrence of HCC were not prevented by HCV eradication (81,82), whereas a study in Japan revealed that the occurrence of HCC was successfully prevented by HCV eradication (83). As complications of non-viral etiologies of chronic liver inflammation, ethnic or genetic backgrounds, stages of liver fibrosis, and genomic or epigenetic alterations in premalignant lesions may affect the outcomes of HCV eradication, further investigations in larger cohorts are necessary to address the controversy regarding the rate of HCC development following HCV eradication.
5. Activation of β-catenin in pulmonary fibrosis and lung cancer
Fibrosis is a common pathology of chronic inflammation in the liver and other organs, including the lungs, heart and kidneys (31,32). Irreversible pulmonary fibrosis, cardiac fibrosis or renal fibrosis leads to organ destruction and subsequent decompensation, which is the final serious condition in patients with non-cancerous diseases. For example, cardiac fibrosis is caused by the transformation of cardiac fibroblasts into myofibroblasts and leads to myocardial stiffness and ventricular dysfunction (32), whereas pulmonary fibrosis is caused by chronic inflammation associated with cancer therapy, cigarette smoking, connective tissue diseases, environmental pollution, infection, pulmonary hypertension and idiopathic pulmonary fibrosis (84,85).
Airway damage-induced canonical WNT/β-catenin signaling activation in alveolar epithelial type II cells promotes the activation and remodeling of interstitial fibroblasts; transient remodeling leads to resolution, whereas persistent remodeling leads to pulmonary fibrosis (31,85). Canonical WNT/β-catenin signaling activation in pulmonary endothelial cells activates perivascular fibroblasts to undergo a myofibroblast-like transition, which also leads to ECM accumulation and increased tissue stiffness, further promoting pulmonary fibrosis (86,87). Pulmonary injuries also induce the chemokine-dependent recruitment of monocytes and their subsequent transition into monocyte-derived alveolar macrophages that express higher levels of pro-inflammatory and pro-fibrotic genes than tissue-resident alveolar macrophages (88). However, β-catenin inhibitors, including ICG-001 and XAV939, ameliorate chronic lung injury and prevent the progression to severe pulmonary fibrosis (89,90). The canonical WNT/β-catenin signaling cascade is involved in the pathogenesis of pulmonary fibrosis.
Genetic alterations in the canonical WNT/β-catenin signaling regulators are relatively rare in human lung cancer (91). However, lung CSCs differentiate into WNT-producing supporting cells to maintain the stemness of CSCs and promote the expansion of bulk tumor cells (92). The upregulation of RSPO2 or RSPO3 leads to canonical WNT/β-catenin signaling activation in patient-derived xenograft (PDX) models of human lung cancer (93), and nuclear β-catenin staining is associated with poor prognosis in patients with lung cancer (94,95). Despite relatively infrequent genetic alterations, the canonical WNT/β-catenin signaling cascade is involved in multi-step tumorigenesis in the human lungs through WNT- and RSPO-dependent paracrine signaling.
Receptor tyrosine kinases (RTKs), including ALK, DDR2, EGFR, FGFR1, FGFR2, HER2, MET, NTRK1, RET and ROS1, are aberrantly activated in human lung cancer due to gene amplification, gene fusions or point mutations (96-99). Although ALK inhibitors (alectinib and ceritinib), an ALK/ROS1 inhibitor (crizotinib) and EGFR inhibitors (afatinib, erlotinib, gefitinib and osimertinib) are approved for the treatment of patients with lung cancer, drug resistance and recurrence are difficult to avoid due to acquired mutations in the targeted RTKs, the by-passed activation of other RTKs and β-catenin signaling activation (34). Therapy-related chronic inflammation, in addition to cancer-cell plasticity and intra-tumor heterogeneity, lead to resistance to RTK-targeted therapeutics, in part through canonical WNT signaling activation.
6. Therapeutics targeting β-catenin for preventing organ fibrosis or treating cancer
β-catenin is involved in chronic inflammation, organ fibrosis and carcinogenesis; however, β-catenin lacking intrinsic enzymatic activity is a difficult target for drug development. Antibody-based or decoy-receptor drugs targeting ligands or receptors involved in canonical WNT signaling and small-molecule compounds targeting porcupine (PORCN), tankyrase (TNKS) and β-catenin PPIs have been developed as β-catenin inhibitors for preclinical studies and/or clinical trials (34). In addition to these investigational drugs, small-molecule compounds targeting epigenetic/transcriptional regulators involved in β-catenin-dependent transcription and antibody- or peptide-based drugs binding to β-catenin-target gene products have also been suggested as β-catenin inhibitors. β-catenin-targeted therapeutics are functionally classified as follows: i) β-catenin inhibitors targeting upstream regulators, ii) β-catenin inhibitors targeting PPIs, iii) β-catenin inhibitors targeting epigenetic regulators, iv) β-catenin inhibitors targeting mediator complexes, and v) β-catenin inhibitors targeting transcriptional outputs (Fig. 3). Follows is a discussion of the pros and cons of each β-catenin inhibitor class.
Anti-FZD1/2/5/7/8 monoclonal antibody (mAb) (vantictumab) (100), anti-FZD5 mAb (IgG-2919) (101), anti-RSPO3 mAb (rosmantuzumab) (102), FZD8-Fc (ipafricept) (103), PORCN inhibitors (ETC-159, GNF6231, WNT-C59 and WNT974) (104-107) and TNKS inhibitors (AZ1366, G007-LK, NVP-TNKS656 and XAV939) (108-111) are therapeutics targeting upstream regulators of β-catenin (Fig. 3). The on-target effects on β-catenin-independent WNT signaling cascades are potential risks for anti-FZD mAbs, FZD8-Fc and PORCN inhibitors, whereas the on-target effects on WNT-independent signaling cascades are potential risks for TNKS inhibitors (34). ETC-159, ipafricept, rosmantuzumab, vantictumab and WNT974 are in clinical trials for the treatment of cancer patients.
β-catenin inhibitors targeting PPIs
CGP049090 (112), CWP232228 (113), E7386 (114), ICG-001 (89), LF3 (115) and PRI-724 (116) are representative therapeutics targeting β-catenin PPIs (Fig. 3). CGP049090, CWP232228 and LF3 inhibit the PPI between β-catenin and TCF, whereas E7386, ICG-001 and PRI-724 inhibit the PPI between β-catenin and CREBBP. Although E7386, ICG-001 and PRI-724 are claimed to repress CREBBP-dependent stemness-related transcription and reciprocally enhance EP300-dependent differentiation-related transcription, this hypothesis remains to be generalized for various types of primary tumors with complex genetic alterations. In addition, the specificities of therapeutics targeting β-catenin PPI remain to be elucidated. E7386 is in a clinical trial for cancer patients, whereas PRI-724 is in clinical trials for patients with cancer or liver fibrosis.
Epigenetic components that permit access of the β-catenin complex to the promoter and enhancer regions of its target genes are downstream regulators of β-catenin-dependent transcription (Fig. 3). JMJD2A (KDM4A), JMJD2B (KDM4B) and JMJD2C (KDM4C) are Jumonji domain-containing enzymes that demethylate histone H3 at K9 and K36 (H3K9 and H3K36) (117,118). JMJD2C associated with β-catenin and chromatin is required for the expression of CCND1 and cell growth in colorectal cancer cells (119). Mouse Jmjd2a and Jmjd2c are required for the self-renewal of embryonic stem cells (ESCs) (120), and Jmjd2c associated with a mediator complex is required for the lineage-specific gene expression and multi-lineage differentiation of ESCs (121). PKF118-310 was initially identified as a compound that inhibits β-catenin-dependent transcription via inhibition of the interaction between β-catenin and TCF7L2, and PKF118-310 has been re-discovered as a JMJD2A inhibitor (8,122,123). PKF118-310 has been shown to exert antitumor effects on colorectal cancer and prostate cancer in vitro and breast cancer and HCC in vivo (122,124,125). PKF118-310 also exerts antifibrotic effects in mouse models of dermal fibrosis (126). Other epigenetic regulators, including EZH2 (127,128), KDM1A (LSD1) (129) and PRMT5 (130), are also involved in canonical WNT/β-catenin signaling activation in certain contexts. As epigenetic regulators are desirable targets in the field of clinical oncology (127,131-134), EZH2 inhibitors, including GSK2816126 and tazemetostat/EPZ-6438), KDM1A inhibitors, including GSK2879552 and pargyline, and PRMT5 inhibitors, including GSK3235025/EPZ015666 and PJ-68, have been developed; however, the mechanisms of action of these investigational drugs on β-catenin-dependent transcription require further clarification to identify biomarkers for patient selection. PKF118-310 is a promising compound to be optimized for the treatment of patients with β-catenin-dependent fibrosis and cancer.
β-catenin inhibitors targeting mediator complexes
Mediator complexes that assemble transcription factors, cofactors and other regulators of RNA polymerase II-mediated mRNA synthesis are involved in the β-catenin-dependent transcription of oncogenic targets, including CCND1 and MYC (135-137) (Fig. 3). β-catenin binds to MED12, which associates with MED13, cyclin C (CCNC) and CDK8/19 to form the kinase module of the mediator complex. As CDK8 and CDK19 are key components of the mediator complex, CCT251545 (138,139) and cortistatin A (140,141) have been characterized as CDK8/19 inhibitors that suppress β-catenin-dependent transcription and the in vivo tumorigenesis of colorectal cancer, breast cancer and acute myeloid leukemia. CDK8/19 phosphorylates mediator complex components (CCNC, MED12, MED13, MED14 and MED26), epigenetic regulators (BCL9, BPTF, BRD9, KDM3A, MLL2, SETD1A and SIRT1) and transcription factors or cofactors (ATF7, FOXC1, KLF12 and STAT1) (141). Additionally, mediator complexes are involved in β-catenin-dependent transcription and transcription dependent on other transcription factors (136,137). Due to the unknown on-target effects associated with the various functions of CDK9/18 and mediator complexes, the application of CDK9/18 inhibitors for the treatment of patients with WNT-driven cancer has been suspended at the preclinical stage.
ABCB1, BAMBI, CD44, CLDN1, CTLA4, FZD7, JAG1, LGR5, NOTCH2, NRCAM, RNF43, TNFRSF19 and ZNRF3 are representative β-catenin target genes that encode transmembrane proteins (Fig. 1C). For example, the CD44v6 isoform that functions as a positive regulator of canonical WNT, CXCL12 (SDF1), FGF2, HGF, OPN and VEGF signaling in CSCs is involved in malignant phenotypical characteristics, including the EMT, tumor cell invasion and metastasis, therapeutic resistance and recurrence (142-145). FZD7 is a seven-transmembrane receptor, which transduces canonical and non-canonical WNT signaling in a context-dependent manner, whereas LGR5 is a seven-transmembrane receptor, which transduces RSPO signaling and potentiates WNT signaling through FZD receptors (8,24,34,146-149). Other transmembrane-type β-catenin signaling outputs are also involved in various pathophysiological aspects of human diseases.
As transmembrane proteins expressed on tumor cells are appropriate targets for the development of peptide-based drugs (142), mAbs, antibody-drug conjugates (ADCs), bi-specific antibodies (bsAbs) and chimeric antigen receptor-modified T cells (150-155), drugs targeting CD44v6, FZD7 and LGR5 are under development as functional β-catenin inhibitors. CD44v6 CAR-T cells (156) and anti-LGR5 ADCs (157,158) and are in preclinical stages, whereas the phase I clinical trial of anti-CD44v6 ADC (bivatuzumab mertansine) for patients with head and neck squamous cell carcinoma was terminated due to severe on-target skin toxicities (159). A peptide-based CD44v6 inhibitor (AMC303) (160) is in a phase I clinical trial for the treatment of patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT03009214); anti-FZD7 mAb (vantictumab), which cross-reacts with FZD1, FZD2, FZD5 and FZD8 (100), is in phase I clinical trials for cancer patients, as mentioned above (ClinicalTrials.gov Identifier: NCT01957007 and NCT01973309); anti-LGR5 mAb (BNC101) (161) is also in a phase I clinical trial for cancer patients (ClinicalTrials.gov Identifier: NCT02726334). Antibody- or peptide-based drugs are promising options for the treatment of β-catenin-driven human diseases; however, further evaluation of the benefits, costs and on-target toxicities are necessary prior to clinical application.
7. Multi-layered prevention and treatment of β-catenin- related diseases
Clinical medicine, particularly clinical oncology, is moving toward genomics-based personalized medicine due to the development of nucleotide sequence technologies. Such personalized medicine is expected to further evolve into omics- and clinical record-based precision medicine with relatively inexpensive costs due to increasing medical expenses in aging societies (162). Genomics-based testing platforms, including MSK-IMPACT (43), FoundationOne (163) and Oncomine Comprehensive Panel (164), and organoid- or PDX-based drug screening (165-167) are useful tools for the prescription of targeted therapeutics; however, there remain unmet medical needs for patients with refractory cancer driven by gain-of-function mutations in non-enzymatic oncogenes, including CTNNB1 and KRAS, or loss-of-function mutations in tumor-suppressor genes, including APC and TP53.
β-catenin signaling is involved in myofibroblast activation and subsequent organ fibrosis (Fig. 2A), whereas the activation of β-catenin and NF-κB signaling is involved in field cancerization in the liver associated with HBV, HCV and other etiologies, and field cancerization in the stomach associated with H. pylori infection (Fig. 2B). Vaccines against HBV and H. pylori are available for the prevention of cancer-associated infections (168,169). The eradication of HCV and H. pylori are optimal choices for the first-line prevention of HCC and gastric cancer, respectively (Fig. 2C); however, pathogen eradication is not always successful and may occur too late to reverse the process of field cancerization. β-catenin inhibitors are expected to be applicable for organ fibrosis prevention, second-line HCC prevention and treating β-catenin-driven cancer (Fig. 2C). Although β-catenin without intrinsic enzymatic activity is difficult to target in drug development, several classes of investigational β-catenin inhibitors (Fig. 3) are in preclinical stages or clinical trials for treating patients with β-catenin-related diseases. The multi-layered prevention and treatment strategy of β-catenin-related human diseases is realistic at present and necessary for the implementation of precision medicine in the future.
Funding
This study was financially supported in part by a grant-in-aid for the Knowledgebase Project from M. Katoh's Fund.
Availability of data and materials
Not applicable.
Authors' contributions
MK analyzed the literatures, designed and wrote the study, and produced the figures.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The author declares that he has no competing interests.
Acknowledgments
Not applicable.
ReferencesKatohMKatohMMolecular genetics and targeted therapy of WNT-related human diseases (Review)405876062017287311485547940TakeichiMDynamic contacts: Rearranging adherens junctions to drive epithelial remodelling15397410201410.1038/nrm380224824068McCreaPDGottardiCJBeyond β-catenin: Prospects for a larger catenin network in the nucleus175564201610.1038/nrm.2015.3KufeDWMUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches3210731081201310.1038/onc.2012.158LiuQChengZLuoLYangYZhangZMaHChenTHuangXLinSYJinMC-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis736800368132016271671105095040KlausABirchmeierWWnt signalling and its impact on development and cancer8387398200810.1038/nrc238918432252VaqueroJNguyen Ho-BouldoiresTHClapéronAFouassierLRole of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: From signaling regulation to clinical relevance3630673079201710.1038/onc.2016.46228068322KatohMKatohMWNT signaling pathway and stem cell signaling network1340424045200710.1158/1078-0432.CCR-06-231617634527ValentaTHausmannGBaslerKThe many faces and functions of β-catenin3127142736201210.1038/emboj.2012.150226174223380220LoYHNoahTKChenMSZouWBorrasEVilarEShroyerNFSPDEF induces quiescence of colorectal cancer cells by changing the transcriptional targets of β-catenin153205218.e8201710.1053/j.gastro.2017.03.048FrescasDPaganoMDeregulated proteolysis by the F-box proteins SKP2 and β-TrCP: Tipping the scales of cancer8438449200810.1038/nrc2396185002452711846NovellasdemuntLFoglizzoVCuadradoLAntasPKucharskaAEnchevaVSnijdersAPLiVSWUSP7 is a tumor-specific WNT activator for APC-mutated colorectal cancer by mediating β-catenin deubiquitination21612627201710.1016/j.celrep.2017.09.072290458315656747HoffmeyerKJunghansDKanzlerBKemlerRTrimethylation and acetylation of β-catenin at Lysine 49 represent key elements in ESC pluripotency1828152824201710.1016/j.celrep.2017.02.07628329675AlokALeiZJagannathanNSKaurSHarmstonNRozenSGTucker-KelloggLVirshupDMWnt proteins synergize to activate β-catenin signaling13015321544201710.1242/jcs.19809328289266HerbstAJurinovicVKrebsSThiemeSEBlumHGökeBKolligsFTComprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling1574201410.1186/1471-2164-15-74WatanabeKBiesingerJSalmansMLRobertsBSArthurWTClearyMAndersenBXieXDaiXIntegrative ChIP-seq/microarray analysis identifies a CTNNB1 target signature enriched in intestinal stem cells and colon cancer9e92317201410.1371/journal.pone.0092317246515223961325FunaNSSchachterKALerdrupMEkbergJHessKDietrichNHonoréCHansenKSembHβ-Catenin regulates primitive streak induction through collaborative interactions with SMAD2/SMAD3 and OCT416639652201510.1016/j.stem.2015.03.00825921273CondelloSMorganCANagdasSCaoLTurekJHurleyTDMateiDβ-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids3422972308201510.1038/onc.2014.178SprangerSBaoRGajewskiTFMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity523231235201510.1038/nature1440425970248YunEJZhouJLinCJHernandezEFazliLGleaveMHsiehJTTargeting cancer stem cells in castration-resistant prostate cancer22670679201610.1158/1078-0432.CCR-15-0190MiwaNFuruseMTsukitaSNiikawaNNakamuraYFurukawaYInvolvement of Claudin-1 in the β-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers12469476200110.3727/096504001108747477ShahKVChienAJYeeCMoonRTCTLA-4 is a direct target of Wnt/β-catenin signaling and is expressed in human melanoma tumors12828702879200810.1038/jid.2008.170185631803135173YanKSJandaCYChangJZhengGXYLarkinKALucaVCChiaLAMahATHanATerryJMNon-equivalence of Wnt and R-spondin ligands during Lgr5+ intestinal stem-cell self-renewal545238242201710.1038/nature22313284678205641471KaurAWebsterMRWeeraratnaATIn the Wnt-er of life: Wnt signalling in melanoma and ageing11512731279201610.1038/bjc.2016.332277648445129830RavindranathAYuenHFChanKKGrillsCFennellDALappinTREl-TananiMWnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer105542551201110.1038/bjc.2011.269217723333170969GnemmiVBouillezAGaudelotKHémonBRingotBPottierNGlowackiFVillersAVindrieuxDCauffiezCMUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/β-catenin pathway and interaction with SNAIL promoter346225236201410.1016/j.canlet.2013.12.02924384091LowKCTergaonkarVTelomerase: Central regulator of all of the hallmarks of cancer38426434201310.1016/j.tibs.2013.07.00123932019SchönSFliermanIOfnerAStahringerAHoldtLMKolligsFTHerbstAβ-catenin regulates NF-κB activity via TNFRSF19 in colorectal cancer cells13518001811201410.1002/ijc.28839De Jaime-SogueroAAulicinoFErtaylanGGriegoACerratoATallamADel SolACosmaMPLluisFWnt/Tcf1 pathway restricts embryonic stem cell cycle through activation of the Ink4/Arf locus13e1006682201710.1371/journal.pgen.1006682283464625386305RingAKimYMKahnMWnt/catenin signaling in adult stem cell physiology and disease10512525201410.1007/s12015-014-9515-2BatallerRBrennerDALiver fibrosis115209218200510.1172/JCI2428215690074546435WynnTARamalingamTRMechanisms of fibrosis: Therapeutic translation for fibrotic disease1810281040201210.1038/nm.2807227725643405917MongaSPβ-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis14812941310201510.1053/j.gastro.2015.02.056257472744494085KatohMCanonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity5113571369201710.3892/ijo.2017.4129290486605642388GuichardCAmaddeoGImbeaudSLadeiroYPelletierLMaadIBCalderaroJBioulac-SagePLetexierMDegosFIntegrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma44694698201210.1038/ng.2256225615173819251KandothCMcLellanMDVandinFYeKNiuBLuCXieMZhangQMcMichaelJFWyczalkowskiMAMutational landscape and significance across 12 major cancer types502333339201310.1038/nature12634241322903927368Cancer Genome Atlas Research NetworkComprehensive molecular characterization of gastric adenocarcinoma513202209201410.1038/nature13480250793174170219RobinsonDVan AllenEMWuYMSchultzNLonigroRJMosqueraJMMontgomeryBTaplinMEPritchardCCAttardGIntegrative clinical genomics of advanced prostate cancer16112151228201510.1016/j.cell.2015.05.001260004894484602TeoAEGargSShaikhLHZhouJKaret FranklFEGurnellMHapperfieldLMarkerABienzMAzizanEABrownMJPregnancy, primary aldosteronism, and adrenal CTNNB1 mutations37314291436201510.1056/NEJMoa1504869263979494612399BaileyPChangDKNonesKJohnsALPatchAMGingrasMCMillerDKChristANBruxnerTJQuinnMCGenomic analyses identify molecular subtypes of pancreatic cancer5314752201610.1038/nature1696526909576Cancer Genome Atlas NetworkComprehensive genomic characterization of head and neck squamous cell carcinomas517576582201510.1038/nature14129256314454311405Cancer Genome Atlas Research NetworkAsan UniversityBC Cancer AgencyBrigham and Women's HospitalBroad InstituteBrown UniversityCase Western Reserve UniversityDana-Farber Cancer InstituteDuke UniversityIntegrated genomic characterization of oesophageal carcinoma541169175201710.1038/nature20805280520615651175ZehirABenayedRShahRHSyedAMiddhaSKimHRSrinivasanPGaoJChakravartyDDevlinSMMutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients23703713201710.1038/nm.4333284813595461196KaurAWebsterMRMarchbankKBeheraRNdoyeAKugelCHIIIDangVMAppletonJO'ConnellMPChengPsFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance532250254201610.1038/nature17392270429334833579WebsterMRKugelCHIIIWeeraratnaATThe Wnts of change: How Wnts regulate phenotype switching in melanoma18562442512015265462684668201BuiTSchadeBCardiffRDAinaOHSanguin-GendreauVMullerWJβ-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model114E707E716201710.1073/pnas.1610383114BeltranHPrandiDMosqueraJMBenelliMPucaLCyrtaJMarotzCGiannopoulouEChakravarthiBVVaramballySDivergent clonal evolution of castration-resistant neuroendocrine prostate cancer22298305201610.1038/nm.4045268551484777652RheinbayEParasuramanPGrimsbyJTiaoGEngreitzJMKimJLawrenceMSTaylor-WeinerARodriguez-CuevasSRosenbergMRecurrent and functional regulatory mutations in breast cancer5475560201710.1038/nature22992286582085563978BugaytsovaJABjörnhamOChernovYAGideonssonPHenrikssonSMendezMSjöströmRMahdaviJShevtsovaAIlverDHelicobacter pylori adapts to chronic infection and gastric disease via pH-responsive BabA-mediated adherence21376389201710.1016/j.chom.2017.02.013282793475392239JavaheriAKruseTMoonensKMejías-LuqueRDebraekeleerAAscheCITegtmeyerNKalaliBBachNCSieberSAHelicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs216189201610.1038/nmicrobiol.2016.18927748768SalamaNRHartungMLMüllerALife in the human stomach: Persistence strategies of the bacterial pathogen Helicobacter pylori11385399201310.1038/nrmicro3016236523243733401YamaokaYGrahamDYHelicobacter pylori virulence and cancer pathogenesis1014871500201410.2217/fon.14.29250527574197059KäbischRMejías-LuqueRGerhardMPrinzCInvolvement of Toll-like receptors on Helicobacter pylori-induced immunity9e104804201410.1371/journal.pone.0104804251537034143222McCrackenKWCatáEMCrawfordCMSinagogaKLSchumacherMRockichBETsaiYHMayhewCNSpenceJRZavrosYWellsJMModelling human development and disease in pluripotent stem cell-derived gastric organoids516400404201410.1038/nature13863253637764270898Bertaux-SkeirikNFengRSchumacherMALiJMaheMMEngevikACJavierJEPeekRMJrOttemannKOrian-RousseauVCD44 plays a functional role in Helicobacter pylori-induced epithelial cell proliferation112e1004663201510.1371/journal.ppat.1004663SongXXinNWangWZhaoCWnt/β-catenin, an oncogenic pathway targeted by H. pylori in gastric carcinogenesis63557935588201510.18632/oncotarget.5758264179324742126SigalMLoganCYKapalczynskaMMollenkopfHJBergerHWiedenmannBNusseRAmievaMRMeyerTFStromal R-spondin orchestrates gastric epithelial stem cells and gland homeostasis548451455201710.1038/nature2364228813421KatohMHiraiMSugimuraTTeradaMCloning, expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family1387387619968761309KatohMKirikoshiHTerasakiHShiokawaKWNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT-β-catenin-TCF signaling pathway28910931098200110.1006/bbrc.2001.607611741304JiangXCongFNovel regulation of Wnt signaling at the proximal membrane level41773783201610.1016/j.tibs.2016.06.00327377711MilneANCarneiroFO'MorainCOfferhausGJNature meets nurture: Molecular genetics of gastric cancer126615628200910.1007/s00439-009-0722-x196576732771140LeodolterAAlonsoSGonzálezBEbertMPViethMRöckenCWexTPeitzUMalfertheinerPPeruchoMSomatic DNA hypomethylation in H. pylori-associated high-risk gastritis and gastric cancer: Enhanced somatic hypomethylation associates with advanced stage cancer6e85201510.1038/ctg.2015.14259288084459532AjaniJALeeJSanoTJanjigianYYFanDSongSGastric adenocarcinoma317036201710.1038/nrdp.2017.3628569272HuhCWYounYHJung daHParkJJKimJHParkHEarly attempts to eradicate Helicobacter pylori after endoscopic resection of gastric neoplasm significantly improve eradication success rates11e0162258201610.1371/journal.pone.0162258275886795010208DangBNGrahamDYHelicobacter pylori infection and antibiotic resistance: A WHO high priority?14383384201710.1038/nrgastro.2017.5728465548OsumiHFujisakiJSuganumaTHoriuchiYOmaeMYoshioTIshiyamaATsuchidaTMikiKA significant increase in the pepsinogen I/II ratio is a reliable biomarker for successfulHelicobacter pylori eradication12e0183980201710.1371/journal.pone.0183980SetaTTakahashiYNoguchiYShikataSSakaiTSakaiKYamashitaYNakayamaTEffectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference12e0183321201710.1371/journal.pone.0183321288176285560713SmythMJNgiowSFRibasATengMWCombination cancer immunotherapies tailored to the tumour microenvironment13143158201610.1038/nrclinonc.2015.209ArzumanyanAReisHMFeitelsonMAPathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma13123135201310.1038/nrc344923344543TouboulTChenSToCCMora-CastillaSSabatiniKTukeyRHLaurentLCStage-specific regulation of the WNT/β-catenin pathway enhances differentiation of hESCs into hepatocytes6413151326201610.1016/j.jhep.2016.02.028269216905010388Planas-PazLOrsiniVBoulterLCalabreseDPikiolekMNigschFXieYRomaGDonovanAMartiPThe RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size18467479201610.1038/ncb333727088858OkabeHYangJSylakowskiKYovchevMMiyagawaYNagarajanSChikinaMThompsonMOertelMBabaHWnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice6416521666201610.1002/hep.28774275336195074849LiJHuSBWangLYZhangXZhouXYangBLiJHXiongJLiuNLiYAutophagy-dependent generation of Axin2+ cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis3667256737201710.1038/onc.2017.272287831775717078KuijkEWRasmussenSBlokzijlFHuchMGehartHToonenPBegthelHCleversHGeurtsAMCuppenEGeneration and characterization of rat liver stem cell lines and their engraftment in a rat model of liver failure622154201610.1038/srep22154269159504768167YinXYiHWangLWuWWuXYuLRSPOs facilitated HSC activation and promoted hepatic fibrogenesis76376763778201610.18632/oncotarget.11654275723185325402TokunagaYOsawaYOhtsukiTHayashiYYamajiKYamaneDHaraMMunekataKTsukiyama-KoharaKHishimaTSelective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model7325201710.1038/s41598-017-00282-wTaoJXuEZhaoYSinghSLiXCouchyGChenXZucman-RossiJChikinaMMongaSPModeling a human hepatocellular carcinoma subset in mice through coexpression of Met and point-mutant β-catenin6415871605201610.1002/hep.28601270971165073058ZhangJLaiWLiQYuYJinJGuoWZhouXLiuXWangYA novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models491469477201710.1016/j.bbrc.2017.07.04128698142LambYNGlecaprevir/pibrentasvir: First global approval7717971804201710.1007/s40265-017-0817-y28929412NehraVRizzaSATemesgenZSofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection53177189201710.1358/dot.2017.53.3.2604176ContiFBuonfiglioliFScuteriACrespiCBolondiLCaraceniPFoschiFGLenziMMazzellaGVerucchiGEarly occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals65727733201610.1016/j.jhep.2016.06.01527349488ReigMMariñoZPerellóCIñarrairaeguiMRibeiroALensSDíazAVilanaRDarnellAVarelaMUnexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy65719726201610.1016/j.jhep.2016.04.00827084592KobayashiMSuzukiFFujiyamaSKawamuraYSezakiHHosakaTAkutaNSuzukiYSaitohSAraseYSustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection89476483201710.1002/jmv.24663SelmanMLópez-OtínCPardoAAge-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis48538552201610.1183/13993003.00398-201627390284KnudsenLRuppertCOchsMTissue remodelling in pulmonary fibrosis367607626201710.1007/s00441-016-2543-2CaoZLisRGinsbergMChavezDShidoKRabbanySYFongGHSakmarTPRafiiSDingBSTargeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis22154162201610.1038/nm.4035267798144872630Andersson-SjölandAKarlssonJCRydell-TörmänenKROS-induced endothelial stress contributes to pulmonary fibrosis through pericytes and Wnt signaling96206217201610.1038/labinvest.2015.100MisharinAVMorales-NebredaLReyfmanPACudaCMWalterJMMcQuattie-PimentelACChenCIAnekallaKRJoshiNWilliamsKJNMonocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span21423872404201710.1084/jem.20162152286943855551573HendersonWRJrChiEYYeXNguyenCTienYTZhouBBorokZKnightDAKahnMInhibition of Wnt/β-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis1071430914314201010.1073/pnas.1001520107ChenXShiCMengXZhangKLiXWangCXiangZHuKHanXInhibition of Wnt/β-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-β1 and FGF-21012230201610.1016/j.yexmp.2016.04.003271128405168757CampbellJDAlexandrovAKimJWalaJBergerAHPedamalluCSShuklaSAGuoGBrooksANMurrayBADistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas48607616201610.1038/ng.3564271587804884143TammelaTSanchez-RiveraFJCetinbasNMWuKJoshiNSHeleniusKParkYAzimiRKerperNRWesselhoeftRAA Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma545355359201710.1038/nature22334284898185903678ChartierCRavalJAxelrodFBondCCainJDee-HoskinsCMaSFischerMMShahJWeiJTherapeutic targeting of tumor-derived R-Spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types76713723201610.1158/0008-5472.CAN-15-056126719531YangYShenJHeJHeJJiangGA meta-analysis of abnormal β-catenin immunohistochemical expression as a prognostic factor in lung cancer: Location is more important18685692201610.1007/s12094-015-1418-4JinJZhanPKatohMKobayashiSSPhanKQianHLiHWangXWangXPrognostic significance of β-catenin expression in patients with non-small cell lung cancer: A meta-analysis697108201710.21037/tlcr.2017.02.07283318305344847ManoHALKoma: A cancer subtype with a shared target2495502201210.1158/2159-8290.CD-12-000922614325SeoJSJuYSLeeWCShinJYLeeJKBleazardTLeeJJungYJKimJOShinJYThe transcriptional landscape and mutational profile of lung adenocarcinoma2221092119201210.1101/gr.145144.112229758053483540HirschFRSudaKWiensJBunnPAJrNew and emerging targeted treatments in advanced non-small-cell lung cancer38810121024201610.1016/S0140-6736(16)31473-827598681KatohMTherapeutics targeting FGF signaling network in human diseases3710811096201610.1016/j.tips.2016.10.00327992319GurneyAAxelrodFBondCJCainJChartierCDoniganLFischerMChaudhariAJiMKapounAMWnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors1091171711722201210.1073/pnas.1120068109227534653406803SteinhartZPavlovicZChandrashekharMHartTWangXZhangXRobitailleMBrownKRJaksaniSOvermeerRGenome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors236068201710.1038/nm.4219BendellJEckhardtGSHochsterHSMorrisVKStricklerJKapounAMWangMXuLMcGuireKDupontJInitial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)69Suppl 1S29S30201610.1016/S0959-8049(16)32668-5LePNMcDermottJDJimenoATargeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28146111201510.1016/j.pharmthera.2014.08.005MadanBKeZHarmstonNHoSYFroisAOAlamJJeyarajDAPendharkarVGhoshKVirshupIHWnt addiction of genetically defined cancers reversed by PORCN inhibition3521972207201610.1038/onc.2015.280ChenCWBeyerCLiuJMaierCLiCTrinh-MinhTXuXColeSHHsiehMHNgNPharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling76773778201710.1136/annrheumdis-2016-21029428153829BlyszczukPMüller-EdenbornBValentaTOstoEStellatoMBehnkeSGlatzKBaslerKLüscherTFDistlerOTransforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis38141314252017LiuJPanSHsiehMHNgNSunFWangTKasibhatlaSSchullerAGLiAGChengDTargeting Wnt-driven cancer through the inhibition of Porcupine by LGK9741102022420229201310.1073/pnas.1314239110242778543864356QuackenbushKSBagbySTaiWMMessersmithWASchreiberAGreeneJKimJWangGPurkeyAPittsTMThe novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance72827328285201610.18632/oncotarget.8626270700885053726LauTChanECallowMWaalerJBoggsJBlakeRAMagnusonSSambroneASchuttenMFiresteinRA novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth7331323144201310.1158/0008-5472.CAN-12-456223539443ShultzMDCheungAKKirbyCAFirestoneBFanJChenCHChenZChinDNDipietroLFazalAIdentification of NVP-TNKS656: The use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor5664956511201310.1021/jm400807n23844574HuangSMMishinaYMLiuSCheungAStegmeierFMichaudGACharlatOWielletteEZhangYWiessnerSTankyrase inhibition stabilizes Axin and antagonizes Wnt signalling461614620200910.1038/nature0835619759537TrautmannMSieversEAretzSKindlerDMichelsSFriedrichsNRennerMKirfelJSteinerSHussSSS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma3350065016201410.1038/onc.2013.443JangGBHongISKimRJLeeSYParkSJLeeESParkJHYunCHChungJULeeKJWnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells7516911702201510.1158/0008-5472.CAN-14-204125660951YamadaKHoriYYamaguchiAMatsukiMTsukamotoSYokoiASembaTOzawaYInoueSYamamotoYProceedings of the American Association for Cancer Research Annual Meeting 20172017 Apr 1–5Washington, DC. PhiladelphiaAACR77Suppl 135177201710.1158/1538-7445.AM2017-5177FangLZhuQNeuenschwanderMSpeckerEWulf-GoldenbergAWeisWIvon KriesJPBirchmeierWA small-molecule antagonist of the β-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis76891901201610.1158/0008-5472.CAN-15-1519ZhouHMakPYMuHMakDHZengZCortesJLiuQAndreeffMCarterBZCombined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo3120652074201710.1038/leu.2017.87283211245628102KatohMKatohMIdentification and characterization of JMJD2 family genes in silico2416231628200415138608BerryWLJanknechtRKDM4/JMJD2 histone demethylases: Epigenetic regulators in cancer cells7329362942201310.1158/0008-5472.CAN-12-4300236445283655154KimTDFuchsJRSchwartzEAbdelhamidDEtterJBerryWLLiCIhnatMALiPKJanknechtRPro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors62362472014249362174058306PedersenMTKooistraSMRadzisheuskayaALaugesenAJohansenJVHaywardDGNilssonJAggerKHelinKContinual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development3515501564201610.15252/embj.201593317272665244899663TomazRAHarmanJLKarimlouDWeaversLFritschLBou-KheirTBellEDel Valle TorresINiakanKKFisherCJmjd2c facilitates the assembly of essential enhancer-protein complexes at the onset of embryonic stem cell differentiation144567579201710.1242/dev.142489280876295312034LepourceletMChenYNFranceDSWangHCrewsPPetersenFBruseoCWoodAWShivdasaniRASmall-molecule antagonists of the oncogenic Tcf/β-catenin protein complex591102200410.1016/S1535-6108(03)00334-914749129FranciGSarnoFNebbiosoAAltucciLIdentification and characterization of PKF118-310 as a KDM4A inhibitor12198205201710.1080/15592294.2016.12490895406213WeiWChuaMSGrepperSSoSSmall molecule antagonists of Tcf4/β-catenin complex inhibit the growth of HCC cells in vitro and in vivo126242624362010HallettRMKondratyevMKGiacomelliAONixonAMLGirgis-GabardoAIlievaDHassellJASmall molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer7e33976201210.1371/journal.pone.0033976BeyerCReichertHAkanHMallanoTSchrammADeesCPalumbo-ZerrKLinNYDistlerAGelseKBlockade of canonical Wnt signalling ameliorates experimental dermal fibrosis7212551258201310.1136/annrheumdis-2012-20254423595143KatohMMutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy8285305201610.2217/epi.15.89ChenJFLuoXXiangLSLiHTZhaLLiNHeJMXieGFXieXLiangHJEZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling741540415582016271727945173077HuangMChenCGengJHanDWangTXieTWangLWangYWangCLeiZChuXTargeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma3981221201710.1016/j.canlet.2017.03.03828377178JinYZhouJXuFJinBCuiLWangYDuXLiJLiPRenRPanJTargeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia12639613980201610.1172/JCI85239276434375096815FeinbergAPKoldobskiyMAGöndörAEpigenetic modulators, modifiers and mediators in cancer aetiology and progression17284299201610.1038/nrg.2016.13269725874888057MoreraLLübbertMJungMTargeting histone methyltransferases and demethylases in clinical trials for cancer therapy857201610.1186/s13148-016-0223-4272226674877953AllisCDJenuweinTThe molecular hallmarks of epigenetic control17487500201610.1038/nrg.2016.5927346641JonesPAIssaJPBaylinSTargeting the cancer epigenome for therapy17630641201610.1038/nrg.2016.9327629931KimSXuXHechtABoyerTGMediator is a transducer of Wnt/beta-catenin signaling2811406614075200610.1074/jbc.M60269620016565090HniszDAbrahamBJLeeTILauASaint-AndréVSigovaAAHokeHAYoungRASuper-enhancers in the control of cell identity and disease155934947201310.1016/j.cell.2013.09.053241198433841062YinJWWangGThe Mediator complex: A master coordinator of transcription and cell lineage development141977987201410.1242/dev.09839224550107MallingerACrumplerSPichowiczMWaalboerDStubbsMAdeniji-PopoolaOWoodBSmithEThaiCHenleyATDiscovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen5817171735201510.1021/jm501436m256800294767141DaleTClarkePAEsdarCWaalboerDAdeniji-PopoolaOOrtiz-RuizMJMallingerASamantRSCzodrowskiPMusilDA selective chemical probe for exploring the role of CDK8 and CDK19 in human disease11973980201510.1038/nchembio.1952265021554677459PelishHELiauBBNitulescuIITangpeerachaikulAPossZCDa SilvaDHCarusoBTArefolovAFadeyiOChristieALMediator kinase inhibition further activates super-enhancer-associated genes in AML526273276201510.1038/nature14904264167494641525PossZCEbmeierCCOdellATTangpeerachaikulALeeTPelishHEShairMDDowellRDOldWMTaatjesDJIdentification of Mediator kinase substrates in human cells using cortistatin A and quantitative phosphoproteomics15436450201610.1016/j.celrep.2016.03.030270505164833653TodaroMGaggianesiMCatalanoVBenfanteAIovinoFBiffoniMApuzzoTSperdutiIVolpeSCocorulloGCD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis14342356201410.1016/j.stem.2014.01.00924607406SchmittMMetzgerMGradlDDavidsonGOrian-RousseauVCD44 functions in Wnt signaling by regulating LRP6 localization and activation22677689201510.1038/cdd.2014.1564356338JiangWGSandersAJKatohMUngefrorenHGieselerFPrinceMThompsonSKZolloMSpanoDDhawanPTissue invasion and metastasis: Molecular, biological and clinical perspectives35SupplS244S275201510.1016/j.semcancer.2015.03.00825865774HiraVVVVan NoordenCJFCarrawayHEMaciejewskiJPMolenaarRJNovel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches1868183198201728363872VincanEFlanaganDJPouliotNBrabletzTSpadernaSVariable FZD7 expression in colorectal cancers indicates regulation by the tumour microenvironment2393113172010SimmonsGEJrPandeySNedeljkovic-KurepaASaxenaMWangAPruittKFrizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells9e98861201410.1371/journal.pone.0098861QiuXJiaoJLiYTianTOverexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ78598785999201610.18632/oncotarget.13292278520645349891CarmonKSGongXYiJWuLThomasAMooreCMMasuhoITimsonDJMartemyanovKALiuQJLGR5 receptor promotes cell-cell adhesion in stem cells and colon cancer cells via the IQGAP1-Rac1 pathway2921498915001201710.1074/jbc.M117.786798287397995592675AyyarBVAroraSO'KennedyRComing-of-age of antibodies in cancer therapeutics3710091028201610.1016/j.tips.2016.09.00527745709BeckAGoetschLDumontetCCorvaïaNStrategies and challenges for the next generation of antibody-drug conjugates16315337201710.1038/nrd.2016.26828303026KontermannREBrinkmannUBispecific antibodies20838847201510.1016/j.drudis.2015.02.00825728220StadlerCRBähr-MahmudHCelikLHebichBRothASRothRPKarikóKTüreciOSahinYElimination of large tumors in mice by mRNA-encoded bispecific antibodies23815817201710.1038/nm.435628604701JacksonHJRafiqSBrentjensRJDriving CAR T-cells forward13370383201610.1038/nrclinonc.2016.36270009585529102DaiHWangYLuXHanWChimeric antigen receptors modified T-cells for cancer therapy108djv439201610.1093/jnci/djv439268193474948566CasucciMNicolis di RobilantBFalconeLCamisaBNorelliMGenovesePGentnerBGullottaFPonzoniMBernardiMCD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma12234613472201310.1182/blood-2013-04-49336124016461JunttilaMRMaoWWangXWangBEPhamTFlygareJYuSFYeeSGoldenbergDFieldsCTargeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer7314ra186201510.1126/scitranslmed.aac7433GongXAzhdariniaAGhoshSCXiongWAnZLiuQCarmonKSLGR5-targeted antibody-drug conjugate eradicates gastrointestinal tumors and prevents recurrence1515801590201610.1158/1535-7163.MCT-16-011427207778RiechelmannHSauterAGolzeWHanftGSchroenCHoermannKErhardtTGronauSPhase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma44823829200810.1016/j.oraloncology.2007.10.00918203652Al-RawiVLaeuferTGlockerKHenekaYMatzke-OgiAAbstract 4911: Allosteric inhibition of the receptor tyrosine kinases c-MET, RON and VEGFR-2 via the co-receptor CD44v6 by the novel compound AMC303Proceedings of the American Association for Cancer Research Annual Meeting 2017Apr 1-5, 2017Washington, DC. PhiladelphiaAACR77Suppl 134911201710.1158/1538-7445.AM2017-4911InglisDJBeaumontDMLavranosTCAbstract 4695: Targeting the LGR5 complex with BNC101 to improve check- point inhibitor therapy in colorectal cancerProceedings of the American Association for Cancer Research Annual Meeting 2017Apr 1-5, 2017Washington, DC. PhiladelphiaAACR77Suppl 134695201710.1158/1538-7445.AM2017-4695KatohMThe integration of genomics testing and functional proteomics in the era of personalized medicine1410551058201710.1080/14789450.2017.139224529039218FramptonGMFichtenholtzAOttoGAWangKDowningSRHeJSchnall-LevinMWhiteJSanfordEMAnPDevelopment and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing3110231031201310.1038/nbt.2696241420495710001HovelsonDHMcDanielASCaniAKJohnsonBRhodesKWilliamsPDBandlaSBienGChoppaPHylandFDevelopment and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors17385399201510.1016/j.neo.2015.03.004259253814415141FriedmanAALetaiAFisherDEFlahertyKTPrecision medicine for cancer with next-generation functional diagnostics15747756201510.1038/nrc4015265368254970460PauliCHopkinsBDPrandiDShawRFedrizziTSbonerASailerVAugelloMPucaLRosatiRPersonalized in vitro and in vivo cancer models to guide precision medicine7462477201710.1158/2159-8290.CD-16-1154283310025413423WhorehousesDCaldasCOf mice and men: Patient-derived xenografts in cancer medicine2823302331201710.1093/annonc/mdx516SingalAGEl-SeragHBHepatocellular carcinoma from epidemiology to prevention: Translating knowledge into practice1321402151201510.1016/j.cgh.2015.08.014262845914618036ZengMMaoXHLiJXTongWDWangBZhangYJGuoGZhaoZJLiLWuDLEfficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: A randomised, double-blind, placebo-controlled, phase 3 trial38614571464201510.1016/S0140-6736(15)60310-526142048
Overview of β-catenin functions at a glance. (A) Protein-protein interactions of β-catenin. β-catenin is a scaffold protein that interacts with adhesion molecules (E-cadherin, N-cadherin and VE-cadherin), transmembrane-type mucins (MUC1 and MUC16), signaling regulators (APC, AXIN1, AXIN2 and NHERF1) and epigenetic or transcriptional regulators (BCL9, BCL9L, CREBBP, EP300, FOXM1, LEF1, MED12, SMARCA4, TCF7, TCF7L1 and TCF7L2). β-catenin is involved in cell adhesion, intracellular signaling and transcription. The functions of β-catenin are regulated by its localization, protein-protein interactions and stability based on post-translational modifications. (B) β-catenin signaling into the nucleus. Canonical WNT signals prevent β-catenin phosphorylation at S33, S37, T41 and S45 to release β-catenin from ubiquitylation-mediated degradation, whereas oncogenic tyrosine kinases phosphorylate β-catenin at Y654 to release β-catenin from cadherin complexes. Stabilized β-catenin is translocated into the nucleus to activate the transcription of TCF/LEF-target genes and transcription dependent on other transcription factors in a cellular context-dependent manner based on epigenetic states and the availability of transcriptional regulators at the regulatory regions of target genes. (C) Transcriptional targets of β-catenin. ABCB1, ALDH1A1, ASCL2, ATF3, AXIN2, BAMBI, CCND1, CD44, CLDN1, CTLA4, DKK1, EDN1, EOMES, FGF18, FGF20, FZD7, GBX1, IL10, JAG1, LEF1, LGR5, MITF, MSX1, MYC, NEUROD1, NKD1, NODAL, NOTCH2, NOTUM, NRCAM, OPN, PAX3, PPARD, PTGS2, RNF43, SNAI1, SP5, TCF7, TERT, TNFRSF19, VEGFA and ZNRF3 are representative β-catenin target genes. β-catenin target genes encoding transmembrane proteins, including CD44v6, FZD7 and LGR5, are shown in red. Transmembrane proteins upregulated by the β-catenin signaling are rational targets of antibody-based drugs, including monoclonal antibodies, antibody-drug conjugates, bi-specific antibodies and chimeric antigen receptor-modified T cells.
Precision medicine of chronic inflammation, organ fibrosis and cancer associated with aberrant β-catenin signaling activation. (A) Chronic persistent inflammation and fibrosis. The failure to resolve acute inflammation leads to chronic inflammation, organ remodeling and fibrosis with the subsequent deposition of extracellular matrix. β-catenin is involved in the activation of myofibroblast-like cells during organ remodeling and fibrosis. (B) Field cancerization in the stomach associated with H. pylori infection. Decades of persistent H. pylori infection lead to the sequential progression of chronic gastritis, atrophic gastritis, intestinal metaplasia and gastric cancer. During chronic active gastritis, H. pylori injects CagA into epithelial cells to activate MET and β-catenin signaling to promote epithelial proliferation. In a subset of human gastric cancer, the canonical WNT/β-catenin signaling cascade is aberrantly activated due to gain-of-function mutations in the CTNNB1 gene or loss-of-function mutations in the APC or RNF43 gene. β-catenin is involved in H. pylori-related chronic active gastritis and gastric cancer. (C) Multi-layered prevention and treatment of β-catenin-related human diseases. Vaccines are available for the prevention of cancer-associated infections with HBV and H. pylori. The eradication of HCV and H. pylori is an optimal first-line prevention of field cancerization in the liver and stomach, respectively. Investigational β-catenin inhibitors are expected to be applicable for organ fibrosis prevention, second-line HCC prevention and treating β-catenin-driven cancer. The multi-layered prevention and treatment strategy of β-catenin-related human diseases is realistic for the practice of personalized medicine at present and necessary for the implementation of precision medicine in the future. H. pylori, Helicobacter pylori; HBV, hepatitis B virus; HCV, hepatitis C virus; RTK, receptor tyrosine kinase; IC, immune checkpoint; mAb, monoclonal antibody.
Investigational β-catenin inhibitors and mechanisms of action. β-catenin-targeted therapeutics are functionally classified as i) β-catenin inhibitors targeting upstream regulators (AZ1366, ETC-159, G007-LK, GNF6231, ipafricept, NVP-TNKS656, rosmantuzumab, vantictumab, WNT-C59, WNT974 and XAV939), ii) β-catenin inhibitors targeting PPIs (CGP049090, CWP232228, E7386, ICG-001, LF3 and PRI-724), iii) β-catenin inhibitors targeting epigenetic regulators (PKF118-310), iv) β-catenin inhibitors targeting mediator complexes (CCT251545 and cortistatin A), and v) β-catenin inhibitors targeting transcriptional outputs [CD44v6 chimeric antigen receptor-modified T cells, CD44v6 inhibitor AMC303, anti-FZD7 mAb cross-reacting with FZD1, FZD2, FZD5 and FZD8 (vantictumab), anti-LGR5 mAb BNC101 and anti-LGR5 ADCs]. AMC303, BNC101, ETC-159, ipafricept, PRI-724, rosmantuzumab, vantictumab and WNT974 are in clinical trials, whereas other investigational β-catenin inhibitors are in preclinical stages. PPIs, protein-protein interactions; ADCs, antibody-drug conjugates; PORCN, porcupine; TNKS, tankyrase; mAb, monoclonal antibody.